Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:53:21.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a modification in the phase II trial assessing the response rate after treatment with p53MVA and pembrolizumab for patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:40:46.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes a detailed explanation of eligibility criteria, such as a person's general health condition or prior treatments, and provides a link for general information about clinical research.
    Difference
    61%
    Check dated 2024-05-22T21:10:07.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change likely indicates an update or revision in the estimated completion date for the medical study related to P53MVA and Pembrolizumab in treating patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
    Difference
    0.0%
    Check dated 2024-05-04T09:45:56.000Z thumbnail image
  9. Check
    44 days ago
    Change Detected
    Summary
    The value 01 03 03 03 01 02 01 03 01 has recently changed to 05 02 08 08 04 30 (Estimated) 05 02 04. This change likely represents an update or modification in the treatment protocol or outcomes assessment for patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer in a phase II clinical trial involving p53MVA and pembrolizumab.
    Difference
    0.6%
    Check dated 2024-05-03T07:11:28.000Z thumbnail image
  10. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:21:20.000Z thumbnail image

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.